A small blood sample contains a finite number of original DNA molecules. Sequencing copies of those molecules more deeply cannot recover a tumor molecule that never entered the analyzed sample.
Original molecule availability, recovery and technical errors place different limits on cell-free DNA analysis. A primary error-suppression study combined molecular barcoding and background correction to improve detection in a defined assay. Another primary comparison examined tumor-informed and tumor-naive assays on matched breast cancer samples. Their findings do not create one universal detection limit: sample input, tracked features and the complete workflow remain part of the result.
Showing the technology this term belongs to: Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/